A carregar...

Bisphosphonates or RANK‐ligand‐inhibitors for men with prostate cancer and bone metastases: a network meta‐analysis

BACKGROUND: Different bone‐modifying agents like bisphosphonates and receptor activator of nuclear factor‐kappa B ligand (RANKL)‐inhibitors are used as supportive treatment in men with prostate cancer and bone metastases to prevent skeletal‐related events (SREs). SREs such as pathologic fractures, s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cochrane Database Syst Rev
Main Authors: Jakob, Tina, Tesfamariam, Yonas Mehari, Macherey, Sascha, Kuhr, Kathrin, Adams, Anne, Monsef, Ina, Heidenreich, Axel, Skoetz, Nicole
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2020
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8095056/
https://ncbi.nlm.nih.gov/pubmed/33270906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013020.pub2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!